PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 84,610 shares, a growth of 44.9% from the March 31st total of 58,396 shares. Based on an average trading volume of 2,670,202 shares, the days-to-cover ratio is currently 0.0 days. Currently, 32.0% of the shares of the company are short sold.

PainReform Stock Performance

PainReform stock traded up $0.05 during mid-day trading on Thursday, reaching $1.93. 41,457 shares of the company were exchanged, compared to its average volume of 767,266. PainReform has a twelve month low of $1.80 and a twelve month high of $17.95. The firm’s 50-day simple moving average is $2.55 and its two-hundred day simple moving average is $3.85. The firm has a market cap of $777,790.00, a PE ratio of 0.00 and a beta of 0.71.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.